- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01601990
Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes
May 17, 2012 updated by: LG Life Sciences
A Multicenter, Multinational, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes
Double-blind, randomized, multicenter, multinational (South Korea and India), parallel group study The study was divided into three parts: part 1 was started with an initial 2 weeks of exercise/diet program followed by another 2 weeks of single-blind placebo run-in period; part 2 was a double-blind treatment period during which eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks; part 3 was for those patients who completed part 1 & 2 and consented to receive another 28 weeks of treatment with LC15-0444 50mg.
Screening tests were performed on the patients who had given the written informed consent.
After 2-week exercise/diet program according to the generally recognized guideline, patients took placebo for another 2 weeks while continuing exercise/diet program.
When the 2-week placebo run-in period was completed, eligible patients were assigned either to placebo or 50 mg of LC15-0444 with 1:1 ratio.
During the total of 24- week treatment period of part 2 after randomization, each patient visited the investigational site at Week 6, 12, 18, and 24.
Completing treatment with placebo or LC15-0444 50mg for 24 weeks after randomization, each patient was asked to provide consent to participate in the part 3 of the study where all the patients were to receive LC15-0444 50mg regardless of the treatment received during the part 2 of the study.
During 28-week treatment period of the part 3, each patient visited the investigational site at Week 30, 38, 46, and 52.
Total study period from screening was 56 weeks per each patient.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
189
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-062
- LG Life Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with Type 2 Diabetes Mellitus
- Adults between 18 and 75 of age
- Patients with HbA1c between 7 % and 11 %
- Patient who had not received any diabetic medications within 6 weeks from screening
- Patients who signed on the consent form after informed on the object, method, and risks of the clinical study
Exclusion Criteria:
- Patients with type 1 diabetes mellitus, gestational diabetes, or secondary diabetes
- Patients who were taking or needed to take any drugs which may affect the control of blood glucose significantly (ex. glucocorticoids)
- Patients who had experienced myocardial infarction, unstable angina or prior history of coronary artery bypass surgery within 6 months prior to screening, or patients with arrhythmia requiring treatment
- Patients with NYHA class II-IV congestive heart failure
- Patients with history of hepatic cirrhosis
- Patients with renal failure or whose creatinine clearance was less than 60mL/min
- Patients with dysfunctional thyroid gland (with abnormal level of TSH)
- Patients with ALT, AST or CPK exceeding 2.5 times of the upper limit of the normal range
- Patients with BMI below 20 kg/m2 or exceeding 40 kg/m2
- Patients with history of asthma or major skin allergy
- Patients taking thyroid hormone, warfarin, dicoumarin or digoxin.
- Patients with history of hypersensitivity to metformin or biguanides.
- Patients who took sodium channel blockers in the last 6 weeks prior to Visit 1.
- Patients who were treated with insulin or glucagon-like peptide-1 (GLP-1) analogue or who took thiazolidinediones (Glitazone) in the last 6 months prior to Visit 1.
- Patients with other reasons who the investigator decided not to be eligible for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
|
Experimental: LC15-0444
|
eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change of HbAlc
Time Frame: from baseline to Week 24
|
from baseline to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c Responder Rate
Time Frame: at Week 24
|
HbA1c Responder Rate at Week 24: HbA1c <7 %, <6.5 %
|
at Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Se Hyun Baek, MD, PhD, Korea University Guro Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2009
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
November 1, 2011
Study Registration Dates
First Submitted
May 15, 2012
First Submitted That Met QC Criteria
May 17, 2012
First Posted (Estimate)
May 18, 2012
Study Record Updates
Last Update Posted (Estimate)
May 18, 2012
Last Update Submitted That Met QC Criteria
May 17, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LG-DPCL005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Placebo group(once daily)
-
Shanghai Fosun Pharmaceutical Industrial Development...RecruitingNeurofibromatosis 1 | NF1 | Plexiform NeurofibromaChina
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Inflazyme Pharmaceuticals LtdCompleted
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Russian Federation, Chile, South Africa, Romania, Slovakia
-
Kowa Company, Ltd.Recruiting
-
Dr. Reddy's Laboratories LimitedCompleted
-
PfizerTerminatedParkinson DiseaseUnited States, France, Israel, Germany
-
Garden of Life, LLCValidcare, LLCActive, not recruitingVaginal HealthUnited States
-
Enterprise Therapeutics LtdCompleted